The National Human Genome Research Institute (NHGRI), a branch of the NIH, has made an agreement with ArQule to support the clinical development of ARQ 092 for the rare disease Proteus syndrome. The NIH says it is currently developing a protocol...
Cancer Genetics (NASDAQ: CGIX) shares climbed 28.33% to $7.70 on Q3 results. The company reported a Q3 loss of $0.41 per share on revenue of $3.22 million.
ArQule (NASDAQ: ARQL) shares jumped 15.09% to $1.22 after the company reported...
Dendreon (NASDAQ: DNDN)
; and its U.S. subsidiaries filed voluntary petitions under Chapter 11 of the Bankruptcy Code in the U.S. Bankruptcy Court for the District of Delaware (the Court) on November 10, 2014.
iBio, Inc. (NYSE: IBIO)...
Q2 2014 Earnings Call
August 05, 2014 9:00 am ET
William B. Boni - Vice President of Investor Relations & Corporate Communications
Paolo Pucci - Chief Executive Officer and Director
The following audio is from a conference call that will begin on May 07, 2014 at 09:00 AM ET. The audio will stream live while the call is active, and can be replayed upon its completion.
Complete Story »
ArQule (NASDAQ: ARQL) shares tumbled 1.08% to touch a new 52-week low of $1.83. ArQule's PEG ratio is -0.77.
Charles & Colvard (NASDAQ: CTHR) shares reached a new 52-week low of $2.58. Charles & Colvard shares have dropped 30.87% over the past...
Arqule Inc. (ARQL)
Q4 2013 Earnings Conference Call
March 5, 2014 9:00 am ET
Paolo Pucci – Chief Executive Officer
Peter Lawrence – President, Chief Operating Officer
Brian Schwartz – Chief Medical Officer
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article.